PURPOSE: Hepatorenal syndrome (HRS) type I is a devastating complication of decompensated cirrhosis. Liver transplantation (LT) offers an excellent survival, and renal replacement therapy (RRT) may be useful until transplantation is available. The survival benefit of RRT in the absence of LT is thought to be short and its benefit in these patients is unknown. To investigate this, we studied the outcome of different therapies (pharmacological, RRT, and LT) in patients with type 1 HRS. METHODS: Medical records (2005-2009) of all cirrhotic patients admitted to our facility with abnormal renal function were reviewed. Patients with preexisting renal disease, diagnosis other than type I HRS, or those without long-term follow-up were excluded. RESULTS: Of 380 patients reviewed, 30 were studied. Nineteen (63.3 %) patients underwent liver transplantation. No difference in baseline liver or renal parameters was noted between those who were or were not transplanted. A decreased mortality was noted (5.3 vs. 64.6 %; p = 0.0005) compared to patients who were not transplanted during the study follow-up median period of 7.8 [CI 1.9-34] months. Among non-transplanted patients, no differences in median survival (8.8 vs. 6.5 months; p = 0.62) or in other parameters studied were found in those patients who received RRT compared to those who did not. Similarly, no survival difference was found comparing those who did or did not receive pharmacological therapy without transplant. CONCLUSION: In type I HRS, LT offers better survival. Among patients who do not receive LT, RRT does not provide an improved survival benefit.
PURPOSE:Hepatorenal syndrome (HRS) type I is a devastating complication of decompensated cirrhosis. Liver transplantation (LT) offers an excellent survival, and renal replacement therapy (RRT) may be useful until transplantation is available. The survival benefit of RRT in the absence of LT is thought to be short and its benefit in these patients is unknown. To investigate this, we studied the outcome of different therapies (pharmacological, RRT, and LT) in patients with type 1 HRS. METHODS: Medical records (2005-2009) of all cirrhotic patients admitted to our facility with abnormal renal function were reviewed. Patients with preexisting renal disease, diagnosis other than type I HRS, or those without long-term follow-up were excluded. RESULTS: Of 380 patients reviewed, 30 were studied. Nineteen (63.3 %) patients underwent liver transplantation. No difference in baseline liver or renal parameters was noted between those who were or were not transplanted. A decreased mortality was noted (5.3 vs. 64.6 %; p = 0.0005) compared to patients who were not transplanted during the study follow-up median period of 7.8 [CI 1.9-34] months. Among non-transplanted patients, no differences in median survival (8.8 vs. 6.5 months; p = 0.62) or in other parameters studied were found in those patients who received RRT compared to those who did not. Similarly, no survival difference was found comparing those who did or did not receive pharmacological therapy without transplant. CONCLUSION: In type I HRS, LT offers better survival. Among patients who do not receive LT, RRT does not provide an improved survival benefit.
Authors: Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben Journal: J Gastroenterol Hepatol Date: 2004-12 Impact factor: 4.029
Authors: D R Jeyarajah; T A Gonwa; M McBride; G Testa; O Abbasoglu; B S Husberg; M F Levy; R M Goldstein; G B Klintmalm Journal: Transplantation Date: 1997-12-27 Impact factor: 4.939
Authors: Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber Journal: Gastroenterology Date: 2008-02-13 Impact factor: 22.682
Authors: C Storm; W M Bernhardt; E Schaeffner; R Neuhaus; A Pascher; P Neuhaus; D Hasper; U Frei; A Kahl Journal: Transplant Proc Date: 2007-03 Impact factor: 1.066
Authors: Sophie McAllister; Jennifer C Lai; Timothy P Copeland; Kirsten L Johansen; Charles E McCulloch; Yuenting D Kwong; Divya Seth; Barbara Grimes; Elaine Ku Journal: Kidney360 Date: 2021-03-03